Achieving Durable Clinical Response with Targeted Treatment for Vitiligo

In this MEDcast episode, Dr Chovatiya and Dr Bunick delve into the advancements in targeted treatments for vitiligo, exploring their potential to provide long-term efficacy and durable clinical response.

0:53 Quality of life impact of vitiligo

2:55 Pathogenesis of vitiligo

5:08 Approaches to vitiligo treatment

8:30 Mechanism of JAK inhibitors

10:25 TRuE-V1 and TRuE-V2 studies for the JAK inhibitor ruxolitinib

14:15 Variation in repigmentation with vitiligo

17:20 Safety of topical ruxolitinib

21:00 Data from the long-term extension trial of ruxolitinib

25:75 Achieving meaningful treatment response in vitiligo

30:15 Investigational biomarkers and treatments for vitiligo

Related Videos
Dawn Eichenfield, MD: Identifying Allergies in Pediatric Dermatology
Hilary Baldwin, MD: IDP-126 May Change Acne Management
Matthew Zirwas, MD: Ruxolitinib Cream and the Eczema JAK Inhibitor Era
Amit Pandya, MD: The Discovery of Oral Tranexamic Acid for Melasma
Dawn Eichenfield, MD: Tips for Managing Severe Acne
Related Content
© 2023 MJH Life Sciences

All rights reserved.